Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Haferlach T, Bennett JM, Löffler H, Gassmann W, Andersen JW, Tuzuner N, Casslleth PA, Fonatsch C, Schoch C, Schlegelberger B, Becher R, Thiel E, Ludwig WD, Sauerland MC, Heinecke A, Büchner T. Haferlach T, et al. Among authors: buchner t. Leuk Lymphoma. 1996 Oct;23(3-4):227-34. doi: 10.3109/10428199609054825. Leuk Lymphoma. 1996. PMID: 9031103 Clinical Trial.
Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, Fonatsch C, Löffler H, Büchner T, Ludwig WD, Thiel E. Schwartz S, et al. Among authors: buchner t. Leuk Lymphoma. 1999 Jun;34(1-2):85-94. doi: 10.3109/10428199909083383. Leuk Lymphoma. 1999. PMID: 10350335
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: buchner t. Leukemia. 2000 Feb;14(2):226-31. doi: 10.1038/sj.leu.2401668. Leukemia. 2000. PMID: 10673737
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wörmann B, Hiddemann W, Büchner T. Lengfelder E, et al. Among authors: buchner t. Leukemia. 2000 Aug;14(8):1362-70. doi: 10.1038/sj.leu.2401843. Leukemia. 2000. PMID: 10942230 Clinical Trial.
Risk-adapted therapy of AML: the AMLCG experience.
Kern W, Haferlach T, Schoch C, Sauerland MC, Heinecke A, Wörmann B, Berdel W, Büchner T, Hiddemann W. Kern W, et al. Among authors: buchner t. Ann Hematol. 2004;83 Suppl 1:S49-51. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124669 Clinical Trial.
401 results